Schaefer, Niklas, Proescholdt, Martin, Steinbach, Joachim P., Weyerbrock, Astrid ORCID: 0000-0001-9060-4462, Hau, Peter ORCID: 0000-0003-3894-5053, Grauer, Oliver, Goldbrunner, Roland, Friedrich, Franziska, Rohde, veit, Ringel, Florian, Schlegel, Uwe, Sabel, Michael, Ronellenfitsch, Michael W., Uhl, Martin, Grau, Stefan, Haenel, Mathias, Schnell, Oliver, Krex, Dietmar, Vajkoczy, Peter, Tabatabai, Ghazaleh ORCID: 0000-0002-3542-8782, Mack, Frederic, Schaub, Christina, Tzaridis, Theophilos ORCID: 0000-0001-9651-1144, Niessen, Michael, Kebir, Sied, Leutgeb, Barbara, Urbach, Horst, Belka, Claus, Stummer, Walter, Glas, Martin and Herrlinger, Ulrich (2018). Quality of life in the GLARIUS trial randomizing bevacizumab/ irinotecan versus temozolomide in newly diagnosed, MGMT-nonmethylated glioblastoma. Neuro-Oncology, 20 (7). S. 975 - 986. CARY: OXFORD UNIV PRESS INC. ISSN 1523-5866

Full text not available from this repository.

Abstract

Background: The GLARIUS trial, which investigated the efficacy of bevacizumab (BEV)/irinotecan (IRI) compared with standard temozolomide in the first-line therapy of O-6-methylguanine-DNA methyltransferase (MGMT)nonmethylated glioblastoma, showed that progression-free survival was significantly prolonged by BEV/IRI, while overall survival was similar in both arms. The present report focuses on quality of life (QoL) and Karnofsky performance score (KPS) during the whole course of the disease. Methods: Patients (n = 170) received standard radiotherapy and were randomized (2: 1) for BEV/IRI or standard temozolomide. At least every 3 months KPS was determined and QoL was measured using the European Organisation for Research and Treatment of Cancer 30-item Core Quality of Life and 20-item Brain Neoplasm questionnaires. A generalized estimating equation (GEE) model evaluated differences in the course of QoL and KPS over time. Also, the time to first deterioration and the time to postprogression deterioration were analyzed separately. Results: In all dimensions of QoL and KPS, GEE analyses and time to first deterioration analyses did not detect significant differences between the treatment arms. At progression, 82% of patients receiving second-line therapy in the standard arm received BEV second-line therapy. For the dimensions of motor dysfunction and headaches, time to postprogression deterioration was prolonged in the standard arm receiving crossover second-line BEV in the vast majority of patients at the time of evaluation. Conclusions: GLARIUS did not find indications for a BEV-induced detrimental effect on QoL in first-line therapy of MGMT-nonmethylated GBM patients. Moreover, GLARIUS provided some indirect corroborative data supporting the notion that BEV may have beneficial effects upon QoL in relapsed GBM.

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Schaefer, NiklasUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Proescholdt, MartinUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Steinbach, Joachim P.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Weyerbrock, AstridUNSPECIFIEDorcid.org/0000-0001-9060-4462UNSPECIFIED
Hau, PeterUNSPECIFIEDorcid.org/0000-0003-3894-5053UNSPECIFIED
Grauer, OliverUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Goldbrunner, RolandUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Friedrich, FranziskaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Rohde, veitUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Ringel, FlorianUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Schlegel, UweUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Sabel, MichaelUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Ronellenfitsch, Michael W.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Uhl, MartinUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Grau, StefanUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Haenel, MathiasUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Schnell, OliverUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Krex, DietmarUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Vajkoczy, PeterUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Tabatabai, GhazalehUNSPECIFIEDorcid.org/0000-0002-3542-8782UNSPECIFIED
Mack, FredericUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Schaub, ChristinaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Tzaridis, TheophilosUNSPECIFIEDorcid.org/0000-0001-9651-1144UNSPECIFIED
Niessen, MichaelUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Kebir, SiedUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Leutgeb, BarbaraUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Urbach, HorstUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Belka, ClausUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Stummer, WalterUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Glas, MartinUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Herrlinger, UlrichUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-181634
DOI: 10.1093/neuonc/nox204
Journal or Publication Title: Neuro-Oncology
Volume: 20
Number: 7
Page Range: S. 975 - 986
Date: 2018
Publisher: OXFORD UNIV PRESS INC
Place of Publication: CARY
ISSN: 1523-5866
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
MINI-MENTAL-STATE; ADJUVANT TEMOZOLOMIDE; PHASE-III; RADIOTHERAPY; CONCOMITANTMultiple languages
Oncology; Clinical NeurologyMultiple languages
Refereed: Yes
URI: http://kups.ub.uni-koeln.de/id/eprint/18163

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item